TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Telomir Pharmaceuticals, Inc. ( (TELO) ) has provided an update.
On May 29, 2025, Telomir Pharmaceuticals announced promising preclinical results for Telomir-1, a treatment for AMD, using a zebrafish model. The study showed that Telomir-1 improved vision, restored retinal structure, reduced oxidative stress, and enhanced survival rates, marking a significant milestone towards its advancement to clinical trials.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of innovative treatments for age-related diseases. The company is currently developing Telomir-1, an oral small molecule candidate aimed at treating age-related macular degeneration (AMD).
Average Trading Volume: 168,314
Technical Sentiment Signal: Sell
Current Market Cap: $62.5M
See more insights into TELO stock on TipRanks’ Stock Analysis page.